ANZICS CTG Endorsed Study
Taking advantage of the unique opportunity offered by the EPO TBI multicentre randomised controlled trial of erythropoietin (EPO) in traumatic brain injury (TBI), this substudy investigated whether in patients with TBI: a) EPO reduced the severity, incidence, and duration of Acute Kidney Injury (AKI); b) the release of kidney injury biomarkers including NGAL were reduced by EPO compared to those receiving placebo; c) the release of kidney injury biomarkers including NGAL predicted the occurrence, severity and duration of AKI in patients with TBI. The EPO-TBI study provided the opportunity to evaluate the benefit of EPO as a treatment for AKI. Study of the biomarkers will provide insight into their release and performance as markers of AKI and their response to therapy.
Elizabeth Moore (Chair / Project Manager), Michael Bailey, Rinaldo Bellomo, and Alistair Nichol.
ANZIC Research Centre, Monash University
606 patients – EPO-AKI; 30 patients – EPO-Biomarkers
Intensive Care Foundation (joint funding for EPO-TBI and POLAR renal substudies) $13,553.
Project Status as of June 2010
The results of this study have been published.
Skrifvars, M. B., Moore, E. et al. Erythropoietin in traumatic brain injury associated acute kidney injury: A randomized controlled trial. Acta Anaesthesiologica Scandinavica 2019. 63(2) 200-207. PMID: 30132785
NCT00987454 (EPO-TBI Study)
ACTRN12609000827235 (EPO-TBI Study)
EUDRA CT: 2011 – 005235 – 22 (EPO-TBI Study)
Elizabeth Moore (mail)